Altus Pharmaceuticals Reports Milestone for Enzyme Replacement Therapy
June 13, 2008
Altus Pharmaceuticals Inc., a biopharmaceutical company focused on oral and injectable protein therapeutics for gastrointestinal and metabolic disorders, announced today the completion of the last patient visit of the Trizytek Phase 3 efficacy trial.
In this trial, Altus is evaluating the efficacy of an oral, non-porcine enzyme replacement therapy for cystic fibrosis patients with exocrine pancreatic insufficiency. Derived from recombinant technology, Trizytek [porcine-free enzymes] is a consistent, stable and pure combination of three active enzymes in a fixed-ratio that is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals.
Trizytek, which was developed with support from the Foundation, has the potential to be the first porcine-free enzyme replacement therapy for patients with pancreatic insufficiency.
Read the full press release issued by Altus Pharmaceuticals.
| 
